Survivorship and palliative care planning for metastatic lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a more patient-centered way to plan survivorship care and comfort (palliative) care for people with metastatic lung cancer. It may help you get support that matches your goals, especially alongside your current targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are a patient at the MGH Cancer Center.
- Your metastatic non-small cell lung cancer (NSCLC) diagnosis was within the last 6 months.
- Your tumor has a driver gene change such as EGFR, ALK, ROS1, or RET, and you are on targeted therapy.
- You can read and respond in English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study collects information from adults with different types and stages of lung cancer to connect molecular test results with treatment choices and outcomes. It may help improve how lung cancer is diagnosed and managed by building a better understanding of what works for different patients.
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.